Comparison of Survivals in Dogs Administered 9.2 Gy TBI and Hematopoietic Grafts From DLA-Nonidentical Unrelated Donors With or Without Posttransplant Immunosuppression
| Immunosuppression3-150 . | No. of Dogs Studied . | Graft Failure . | Survival Days . | Surviving >200 days . | References . | |
|---|---|---|---|---|---|---|
| Median . | Range . | |||||
| None | 72 | 6 | 11 | 7-23 | 0 | 1, 25 and concurrent |
| CSP3-151 | 19 | 8 | 18 | 4->182 | 1/193-152 | 2 and concurrent |
| MTX + CSP3-153 | 16 | 1 | 88 | 5->372 | 4/16 | 2 and concurrent |
| MMF (Group 1)3-155 | 6 | 2 | 18 | 8-28 | 0 | Current study |
| MMF + CSP (Group 2)¶ | 4 | 0 | 8 | 6-98 | 0 | Current study |
| MMF + CSP (Group 3)# | 9 | 0 | >420 | 7->540 | 5/9 | Current study |
| MMF + CSP (Group 4)3-160 | 6 | 0 | >119 | 38->316 | 3/6 | Current study |
| Immunosuppression3-150 . | No. of Dogs Studied . | Graft Failure . | Survival Days . | Surviving >200 days . | References . | |
|---|---|---|---|---|---|---|
| Median . | Range . | |||||
| None | 72 | 6 | 11 | 7-23 | 0 | 1, 25 and concurrent |
| CSP3-151 | 19 | 8 | 18 | 4->182 | 1/193-152 | 2 and concurrent |
| MTX + CSP3-153 | 16 | 1 | 88 | 5->372 | 4/16 | 2 and concurrent |
| MMF (Group 1)3-155 | 6 | 2 | 18 | 8-28 | 0 | Current study |
| MMF + CSP (Group 2)¶ | 4 | 0 | 8 | 6-98 | 0 | Current study |
| MMF + CSP (Group 3)# | 9 | 0 | >420 | 7->540 | 5/9 | Current study |
| MMF + CSP (Group 4)3-160 | 6 | 0 | >119 | 38->316 | 3/6 | Current study |
Long-term survival (comparison between the regimens by 2-sided log-rank test): Group 1 versus no immunosuppression: P = .04, Groups 3 and 4 versus no immunosuppression: P < .0001, Groups 3 and 4 versus CSP: P = .0002, Groups 3 and 4 versus MTX + CSP:P = .078.
Graft failure (proportions compared using Pearson's χ2test): Groups 2 + 3 + 4 versus CSP only: P < .001.
Results are from historical and concurrent controls and studies.
CSP: Cyclosporine, given at doses of 10-12.5 mg/kg twice daily IM on days 0-7 and by mouth on days 8-25 (n = 13) or 10 mg/kg twice daily IV on days 0-9 and 15 mg/kg twice daily on days 10-27 (n = 6).
One dog was clinically free of GVHD and euthanized at day 182. We assume that dog would have become a long-term survivor.
MTX 0.4 mg/kg/d IV at days 1, 3, 6 and 11 in all dogs. In 10 dogs CSP was given at 7.5 mg/kg twice daily IM on days 0-7 and by mouth on days 8-26; 5 mg/kg twice daily by mouth on days 27-50, 2.5 mg/kg twice daily by mouth on days 51-75 and then every other day 2.5 mg/kg twice daily until day 100. In 6 dogs, CSP was given at 10 mg/kg twice daily IV on days 0-6, 15 mg/kg twice daily by mouth on days 7-45.
MMF 10 mg/kg SC twice daily (20 mg/kg/d) on days 0-27.
¶MMF 10 mg/kg SC twice daily (20 mg/kg/d) on days 0-27, CSP 10 mg/kg IV twice daily (20 mg/kg/d) on days 0-9, 15 mg/kg by mouth twice daily (30 mg/kg/d) on days 10-27.
#MMF 6 mg/kg SC twice daily (12 mg/kg/d) on days 0-2, 10 mg/kg SC twice daily (20 mg/kg/d) on days 3-27; CSP 10 mg/kg IV twice daily (20 mg/kg/d) on days 0-9, 15 mg/kg by mouth twice daily (30 mg/kg/d) on days 10-27.
MMF 6 mg/kg SC twice daily (12 mg/kg/d) on days 0-2, 10 mg/kg SC twice daily (20 mg/kg/d) on days 3-20; CSP 5 mg/kg IV twice daily (10 mg/kg/d) on days 0-5, 15 mg/kg by mouth twice daily (30 mg/kg/d) on days 6-20, 7.5 mg/kg twice daily (15 mg/kg/d) on days 21-45, 5 mg/kg by mouth twice daily (10 mg/kg/d) on days 46-75, 3 mg/kg by mouth twice daily (6 mg/kg/d) on days 76-100.